Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 9,649 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Human Clear all
Active, not recruiting Phase 3 Interventional

AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

NCT07368959
View directory record Official record
Conditions
Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Interventions
Combination Product: AURN001 + Y-27632, Placebo
Drug · Other
Lead sponsor
Aurion Biotech
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Mesa, Arizona • Little Rock, Arkansas • Fort Collins, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 2:29 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Human Models of Selective Insulin Resistance: Alpelisib, Part I

NCT06354088
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
Interventions
Alpelisib 300 mg, Placebo, [1-13C] sodium acetate, [6,6-2H2] D-glucose, Mixed Meal Tolerance Test, Nestlé BOOST Plus
Drug · Diagnostic Test · Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 23, 2026, 2:29 PM EDT
Terminated Phase 1Phase 2 Interventional

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

NCT06400303
View directory record Official record
Conditions
Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Interventions
KYV-101, Standard lymphodepletion regimen
Biological · Drug
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Palo Alto, California • Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 23, 2026, 2:29 PM EDT
Enrolling by invitation No phase listed Observational

A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

NCT05768386
View directory record Official record
Conditions
Hemophilia A
Interventions
Not listed
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2040
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 23, 2026, 2:29 PM EDT
Terminated Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

NCT00023790
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer, Non-melanomatous Skin Cancer, Sarcoma
Interventions
silicon phthalocyanine 4
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Oct 23, 2026, 2:29 PM EDT
Completed Not applicable Interventional

Childhood Obesity Treatment: A Maintenance Approach

NCT00301197
View directory record Official record
Conditions
Obesity
Interventions
Behavioral Skills Maintenance, Social Facilitation Maintenance
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 12 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2006 · Synced Oct 23, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone

NCT00376324
View directory record Official record
Conditions
Healthy Subjects
Interventions
Tigecycline
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 10, 2009 · Synced Oct 23, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

NCT04338659
View directory record Official record
Conditions
Advanced Malignant Tumors Lymphomas
Interventions
IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
Biological
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Westwood, Kansas • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 23, 2026, 2:29 PM EDT
Completed Phase 4 Interventional Results available

Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.

NCT00355342
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol 50 mcg BID, Fluticasone Propionate/Salmeterol 250/50 mcg BID, DISKUS inhaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
37
States / cities
Berkeley, California • Fullerton, California • Rancho Mirage, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 23, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Lactoferrin at Two Doses vs. Active Control on Markers of Immune Function

NCT06012669
View directory record Official record
Conditions
Immune Health
Interventions
High dose Human Lactoferrin, Low dose Human Lactoferrin, Active Control Bovine Lactoferrin
Dietary Supplement
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Miami, Florida • Port Saint Lucie, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 23, 2026, 2:29 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Chymase Angiotensin-(1-12) Axis In Hypertensive Disease

NCT05644769
View directory record Official record
Conditions
Hypertension
Interventions
Determine the presence of Human sequence Ang-(1-12) on no medication, Human sequence Ang-(1-12) on Lisinopril 40mg every day
Other · Drug
Lead sponsor
Trinity Hypertension & Metabolic Research Institute
Other
Eligibility
40 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 23, 2026, 2:29 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Intraoperative OCT Guidance of Intraocular Surgery II

NCT03713268
View directory record Official record
Conditions
Macular Holes, Epiretinal Membrane, Diabetic Retinopathy, Retinal Detachment, Retinal Disease, Preretinal Fibrosis, Cataract, Ocular Tumor, Strabismus, Healthy
Interventions
Microscope integrated optical coherence tomography
Device
Lead sponsor
Duke University
Other
Eligibility
4 Weeks and older
Enrollment
262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 2:29 PM EDT
Terminated Phase 2 Interventional Results available

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

NCT04150562
View directory record Official record
Conditions
Clear-Cell Renal Carcinoma
Interventions
rhIL-15, Avelumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 23, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

NCT03397888
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Betrixaban
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 23, 2026, 2:29 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Physiological Effects of ANGPTL3 Variants in Humans

NCT04234724
View directory record Official record
Conditions
Hypocholesterolemia
Interventions
Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 23, 2026, 2:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency

NCT06662188
View directory record Official record
Conditions
SHANK3 Haploinsufficiency, Phelan-McDermid Syndrome
Interventions
JAG201
Genetic
Lead sponsor
Jaguar Gene Therapy, LLC
Industry
Eligibility
2 Years to 9 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 23, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sleep Apnea Study in Adults Using DreamPort-Eclipse and a Traditional Nasal Mask

NCT05818540
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Eclipse novel CPAP mask, ResMed P-10 mask
Device
Lead sponsor
Bleep, LLC
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 23, 2026, 2:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome

NCT07135050
View directory record Official record
Conditions
Pitt Hopkins Syndrome
Interventions
MZ-1866
Genetic
Lead sponsor
Mahzi Therapeutics
Industry
Eligibility
2 Years to 25 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Oakland, California • Aurora, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 2:29 PM EDT
Active, not recruiting Not applicable Interventional

Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses

NCT05864118
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Respiratory pathogen panel PCR test, COVID-19 antibody test
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 23, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Engaging Clinical Champions to Improve HPV Vaccination

NCT05736718
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Champion Announcement Approach Training, Traditional Announcement Approach Training
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
9 Years to 12 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 23, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT03915379
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
JNJ-67571244
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Boston, Massachusetts • Detroit, Michigan • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 23, 2026, 2:29 PM EDT
Not yet recruiting Not applicable Interventional

Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness

NCT07760779
View directory record Official record
Conditions
Nocturia, Insomnia
Interventions
Brief behavioral treatment of insomnia, MI, Control, BBTI+MI
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 2:29 PM EDT
Completed Not applicable Interventional

Study of the Relationship Between Feeding and Late Onset Sepsis and/or Necrotizing Enterocolitis in Low Birth Weight Infants

NCT00005888
View directory record Official record
Conditions
Necrotizing Enterocolitis, Sepsis
Interventions
Fortified Pasteurized Donor Human Milk supplement, Preterm Formula supplement
Behavioral
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years to 96 Hours
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 2:29 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04798027
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 23, 2026, 2:29 PM EDT